nach oben

Current Hypertension Reports

Erschienen in:

01.08.2013 | Secondary Hypertension: Adrenal and Nervous System Mechanisms (S Oparil, Section Editor)

The Sympathetic Nervous System in Chronic Kidney Disease

verfasst von: Sebastian Ewen, Christian Ukena, Dominik Linz, Roland E. Schmieder, Michael Böhm, Felix Mahfoud

Erschienen in: Current Hypertension Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidence has shown that the sympathetic nervous system plays an important role in the pathophysiology and progression of several chronic disorders, e.g., arterial hypertension, cardiac arrhythmias, heart failure, and in particular chronic kidney disease (CKD). Experimental and clinical studies provide evidence that sympathetic inhibition using either sympatholytic pharmacotherapy or catheter-based renal denervation has beneficial effects in patients with CKD. Randomized clinical trials are needed to characterize the underlying pathophysiological mechanisms, and systematically evaluate the therapeutic effects of sympathetic inhibition in this high-risk patient population. In this review current knowledge of the role of the sympathetic nervous system in the development and progression of CKD will be summarized, and novel treatment options targeting sympathetic nervous system activity will be discussed.

•• Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61. doi:10.1016/s0140-6736(12)61272-0. Important overwiev regarding the mortality of CK with and without hypertension.PubMedCrossRef

Borrelli S, De Nicola L, Stanzione G, Conte G, Minutolo R. Resistant hypertension in nondialysis chronic kidney disease. Int J Hypertens. 2013;2013:1–8. doi:10.1155/2013/929183.CrossRef

Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121(4):332–40. doi:10.1016/j.amjmed.2007.11.025.PubMedCrossRef

Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340(17):1321–8. doi:10.1056/NEJM199904293401704.PubMedCrossRef

• Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100(12):1049–57. doi:10.1007/s00392-011-0335-y. Review article on the role of the sympathetic nervous system in different disease states and potential future indication of renal denervation.PubMedCrossRef

DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41(3 Pt 2):621–4. doi:10.1161/01.HYP.0000047205.52509.8A.PubMedCrossRef

Buchner N, Vonend O, Rump LC. Pathophysiology of hypertension: what's new? Herz. 2006;31(4):294–302. doi:10.1007/s00059-006-2821-y.PubMedCrossRef

DiBona GF. Physiology in perspective: The wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633–41. doi:10.1152/ajpregu.00258.2005.PubMedCrossRef

Vonend O, Okonek A, Stegbauer J, Habbel S, Quack I, Rump LC. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovasc Res. 2005;66(2):345–52. doi:10.1016/j.cardiores.2004.12.005.PubMedCrossRef

10.

Ishii M, Ikeda T, Takagi M, Sugimoto T, Atarashi K, Igari T, et al. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension. 1983;5(4):545–51.PubMedCrossRef

11.

• Converse Jr RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–8. doi:10.1056/NEJM199212313272704. Important work about the sympathetic overactivity in patients with CKD.PubMedCrossRef

12.

Recordati G, Moss NG, Genovesi S, Rogenes P. Renal chemoreceptors. J Auton Nerv Syst. 1981;3(2–4):237–51.PubMedCrossRef

13.

Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974–9.PubMedCrossRef

14.

Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846–51. doi:10.1161/HYPERTENSIONAHA.110.164780.PubMedCrossRef

15.

• Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22(2):208–15. Important scientific statement regarding sympathetic hyperactivity in CKD.PubMed

16.

Ditting T, Freisinger W, Siegel K, Fiedler C, Small L, Neuhuber W, et al. Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? Hypertension. 2012;59(2):467–76. doi:10.1161/HYPERTENSIONAHA.111.185538.PubMedCrossRef

17.

Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol. 1994;4(11):1901–7.PubMed

18.

Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol. 1997;10(4):184–7.PubMed

19.

Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 Pt 2):878–82.PubMedCrossRef

20.

Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26(5):861–5.PubMedCrossRef

21.

Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51(3):722–7.PubMedCrossRef

22.

Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002;15(8):717–24.PubMedCrossRef

23.

Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens. 1984;2(4):349–59.PubMed

24.

Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11(6 Pt 1):723–8.PubMedCrossRef

25.

Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12(11):2427–33.PubMed

26.

Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol. 2007;170(3):830–42. doi:10.2353/ajpath.2007.060455.PubMedCrossRef

27.

Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933–9. doi:10.1681/ASN.2008040402.PubMedCrossRef

28.

Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res. 1993;73(3):596–602.PubMedCrossRef

29.

Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262(6 Pt 1):E763–78.PubMed

30.

Carlson SH, Wyss JM. Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep. 2008;10(3):233–40.PubMedCrossRef

31.

Hering D, Zdrojewski Z, Krol E, Kara T, Kucharska W, Somers VK, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens. 2007;25(1):157–61. doi:10.1097/HJH.0b013e3280102d92.PubMedCrossRef

32.

Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15(2):435–41.PubMedCrossRef

33.

Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2620–7. doi:10.2215/CJN.06970711.PubMedCrossRef

34.

Bergamaschi CT, Campos RR, Lopes OU. Rostral ventrolateral medulla : A source of sympathetic activation in rats subjected to long-term treatment with L-NAME. Hypertension. 1999;34(4 Pt 2):744–7.PubMedCrossRef

35.

Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol. 2002;39(4):683–8.PubMedCrossRef

36.

Augustyniak RA, Victor RG, Morgan DA, Zhang W. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R726–32. doi:10.1152/ajpregu.00768.2004.PubMedCrossRef

37.

Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res. 1999;43(3):639–49.PubMedCrossRef

38.

Zanzinger J, Czachurski J, Seller H. Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. Circ Res. 1997;80(4):565–71.PubMedCrossRef

39.

Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999;33(4):937–42.PubMedCrossRef

40.

Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102(13):1536–41.PubMedCrossRef

41.

Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(6):609–15. doi:10.1097/MNH.0b013e328314b6ca.PubMedCrossRef

42.

Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62(1):339–45. doi:10.1046/j.1523-1755.2002.00437.x.PubMedCrossRef

43.

Shi B, Ni Z, Zhou W, Yu Z, Gu L, Mou S, et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med. 2010;21(5):444–8. doi:10.1016/j.ejim.2010.07.001.PubMedCrossRef

44.

Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol. 2004;287(2):H695–703. doi:10.1152/ajpheart.00619.2003.PubMedCrossRef

45.

Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97. doi:10.1161/CIRCULATIONAHA.106.678342.PubMedCrossRef

46.

Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14(2):425–30.PubMedCrossRef

47.

Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275–80. doi:10.1172/JCI24066.PubMed

48.

Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008;117(10):1277–82. doi:10.1161/CIRCULATIONAHA.107.732032.PubMedCrossRef

49.

Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(9):2930–4. doi:10.1093/ndt/gfq857.PubMedCrossRef

50.

Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701–8. doi:10.1016/j.jacc.2010.03.105.PubMedCrossRef

51.

Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int. 2001;60(4):1309–23. doi:10.1046/j.1523-1755.2001.00936.x.PubMedCrossRef

52.

Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–44.PubMedCrossRef

53.

Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, et al. beta-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis. 2011;58(6):939–45. doi:10.1053/j.ajkd.2011.06.024.PubMedCrossRef

54.

Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905–13. doi:10.1038/sj.ki.5001835.PubMed

55.

Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21(9):1709–17. doi:10.1097/01.hjh.0000084733.53355.c3.PubMedCrossRef

56.

Siddiqi L, Joles JA, Oey PL, Blankestijn PJ. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens. 2011;29(11):2176–80. doi:10.1097/HJH.0b013e32834ae3c7.PubMedCrossRef

57.

Mahfoud F. [Renal denervation in hypertension - pro]. Dtsch Med Wochenschr. 2012;137(14):720. doi:10.1055/s-0032-1304839.PubMedCrossRef

58.

• Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. doi:10.1016/S0140-6736(09)60566-3. First-in-man report of renal denervation in patients with resistant hypertension.PubMedCrossRef

59.

• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. doi:10.1016/S0140-6736(10)62039-9. Randomized controlled trial investigating the effect of renal denervation versus medical treatment alone in patients with resistant hypertension.PubMedCrossRef

60.

Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7. doi:10.1161/HYPERTENSIONAHA.110.163014.CrossRef

61.

• Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension. 2012. doi:10.1161/HYPERTENSIONAHA.112.193870. Study showing that renal denervation reduces renal resistive indices and number of patients with micro- and macroalbuminuria, without impairing renal function.

62.

Ott C, Janka R, Schmid A, Titze S, Ditting T, Sobotka PA, et al. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol. 2013. doi:10.2215/CJN.08500812.PubMed

63.

Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens. 2012;14(11):799–801. doi:10.1111/jch.12017.CrossRef

64.

• Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013. doi:10.1016/j.ijcard.2013.01.218. Important work about RDN in patients with ESRD.

65.

Dörr O, Liebetrau C, Mollmann H, Achenbach S, Sedding D, Szardien S, et al. Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol. 2012. doi:10.1016/j.jacc.2012.09.051.PubMed

66.

Zilch O, Vos PF, Oey PL, Cramer MJ, Ligtenberg G, Koomans HA, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens. 2007;25(6):1285–9. doi:10.1097/HJH.0b013e3280f9df85.PubMedCrossRef

67.

Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension. 2010;56(6):1077–82. doi:10.1161/HYPERTENSIONAHA.110.154427.PubMedCrossRef

68.

Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2012;21(1):46–51. doi:10.1097/MNH.0b013e32834db45d.PubMedCrossRef

Titel: The Sympathetic Nervous System in Chronic Kidney Disease
verfasst von: Sebastian Ewen
Christian Ukena
Dominik Linz
Roland E. Schmieder
Michael Böhm
Felix Mahfoud
Publikationsdatum: 01.08.2013
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 4/2013
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0365-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Sympathetic Nervous System in Chronic Kidney Disease

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Gender Differences in Hypertension: Myths and Reality

Aldosterone Mediates Cardiac Fibrosis in the Setting of Hypertension

The Sympathetic Nervous System in Obesity Hypertension

The Role of Home Blood Pressure Telemonitoring in Managing Hypertensive Populations

Primary Hypertension in Children and Adolescents is an Immuno-Metabolic Disease with Hemodynamic Consequences

Generic Drugs for Hypertension: Are They Really Equivalent?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin